|
π’
|
Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.
14 auth.
R. V. van Vollenhoven,
R. Fleischmann,
S. Cohen,
E. Lee,
J. A. GarcΓa Meijide,
Sylke Wagner,
Ε . ForejtovΓ‘,
S. Zwillich,
D. Gruben,
T. Koncz,
...
G. Wallenstein,
S. Krishnaswami,
J. Bradley,
B. Wilkinson
|
9 |
2012 |
9
π’
|
|
π
|
The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.
11 auth.
J. Kremer,
B. Bloom,
F. Breedveld,
J. Coombs,
M. P. Fletcher,
D. Gruben,
...
S. Krishnaswami,
R. Burgos-Vargas,
B. Wilkinson,
C. Zerbini,
S. Zwillich
|
9 |
2009 |
9
π
|
|
π
|
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.
12 auth.
R. Fleischmann,
M. Cutolo,
M. Genovese,
E. Lee,
K. Kanik,
S. Sadis,
...
C. Connell,
D. Gruben,
S. Krishnaswami,
G. Wallenstein,
B. Wilkinson,
S. Zwillich
|
8 |
2012 |
8
π
|
|
π
|
A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.
12 auth.
J. Kremer,
S. Cohen,
B. Wilkinson,
C. Connell,
J. French,
J. GΓ³mez-Reino,
...
D. Gruben,
K. Kanik,
S. Krishnaswami,
V. Pascual-Ramos,
G. Wallenstein,
S. Zwillich
|
8 |
2012 |
8
π
|
|
π
|
Tofacitinib versus methotrexate in rheumatoid arthritis.
12 auth.
E. Lee,
R. Fleischmann,
S. Hall,
B. Wilkinson,
J. Bradley,
D. Gruben,
...
T. Koncz,
S. Krishnaswami,
G. Wallenstein,
C. Zang,
S. Zwillich,
R. V. van Vollenhoven
|
8 |
2014 |
8
π
|
|
π
|
The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis
14 auth.
K. Winthrop,
J. Silverfield,
A. Racewicz,
J. Neal,
E. Lee,
P. Hrycaj,
J. GΓ³mez-Reino,
K. Soma,
C. Mebus,
B. Wilkinson,
...
J. Hodge,
H. Fan,
Tao Wang,
C. Bingham
|
7 |
2015 |
7
π
|
|
π
|
Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis.
10 auth.
M. Boy,
Cunshan Wang,
B. Wilkinson,
V. Chow,
A. Clucas,
J. Krueger,
...
A. Gaweco,
S. Zwillich,
P. Changelian,
G. Chan
|
7 |
2009 |
7
π
|
|
π
|
Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial
10 auth.
J. Coombs,
B. Bloom,
F. Breedveld,
M. P. Fletcher,
D. Gruben,
J. Kremer,
...
R. Burgos-Vargas,
B. Wilkinson,
C. Zerbini,
S. Zwillich
|
7 |
2009 |
7
π
|
|
π’
|
Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques
15 auth.
P. Conaghan,
M. Γstergaard,
M. Bowes,
Chun-Hsin Wu,
T. Fuerst,
D. M. van der Heijde,
F. Irazoque-Palazuelos,
O. Soto-Raices,
P. Hrycaj,
Z. Xie,
...
Richard Y. Zhang,
B. Wyman,
J. Bradley,
K. Soma,
B. Wilkinson
|
6 |
2016 |
6
π’
|
|
π
|
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis
9 auth.
V. Strand,
R. V. van Vollenhoven,
Eun Bong Lee,
R. Fleischmann,
S. Zwillich,
D. Gruben,
...
T. Koncz,
B. Wilkinson,
G. Wallenstein
|
6 |
2016 |
6
π
|
|
π
|
Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial
10 auth.
V. Strand,
E. Lee,
R. Fleischmann,
R. Alten,
T. Koncz,
S. Zwillich,
...
D. Gruben,
B. Wilkinson,
S. Krishnaswami,
G. Wallenstein
|
5 |
2016 |
5
π
|
